BRPI0514829A - domìnios e epitopos da proteìna meningocócica nmb1870 - Google Patents
domìnios e epitopos da proteìna meningocócica nmb1870Info
- Publication number
- BRPI0514829A BRPI0514829A BRPI0514829-4A BRPI0514829A BRPI0514829A BR PI0514829 A BRPI0514829 A BR PI0514829A BR PI0514829 A BRPI0514829 A BR PI0514829A BR PI0514829 A BRPI0514829 A BR PI0514829A
- Authority
- BR
- Brazil
- Prior art keywords
- nmb188
- families
- epitopes
- domains
- nmb1870
- Prior art date
Links
- 108020001580 protein domains Proteins 0.000 title abstract 2
- 101100446533 Neisseria meningitidis serogroup B (strain MC58) fhbP gene Proteins 0.000 abstract 2
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 102400000368 Surface protein Human genes 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
DOMìNIOS E EPITOPOS DA PROTEìNA MENINGOCóCICA NMB187O "NMBl870" é uma proteína de superfície conhecida em Neisseria meningitidis expressa por todos os sorogrupos. Ela tem três famílias distintas. O soro desenvolvido contra certa família é bactericida dentro da mesma família, mas não é ativo contra cepas que expressam uma das outras duas famílias, ou seja, há proteção cruzada intrafamília, mas não interfamílias. Os inventores verificaram que NMB1870 pode ser dividida em domínios, e que nem todos os domínios são necessários para a antigenicidade. Domínios antigênicos podem ser retirados de cada uma das três famílias de NMBl870 e expressos como uma cadeia polipeptídica única. Os inventores também verificaram que NMBl870 expõe alguns de seus epitopos em espirais de superfície situadas entre alfa-hélices, e que a substituição de epitopos da espiral de uma família na posição da espiral em outra família permite que seja produzida NMBl870 quimérica com antigenicidade multifamílias. Dessa forma, são fornecidas proteínas NMB1870 quiméricas que compreendem porções de NMBl870 de diferentes famílias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0419408A GB0419408D0 (en) | 2004-09-01 | 2004-09-01 | 741 chimeric polypeptides |
PCT/IB2005/002968 WO2006024954A2 (en) | 2004-09-01 | 2005-09-01 | Domains and epitopes of meningococcal protein nmb1870 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0514829A true BRPI0514829A (pt) | 2008-06-24 |
Family
ID=33155851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0514829-4A BRPI0514829A (pt) | 2004-09-01 | 2005-09-01 | domìnios e epitopos da proteìna meningocócica nmb1870 |
Country Status (20)
Country | Link |
---|---|
US (1) | US20090285845A1 (pt) |
EP (1) | EP1784419B1 (pt) |
JP (2) | JP4827196B2 (pt) |
CN (1) | CN101031584B (pt) |
AU (1) | AU2005278904B2 (pt) |
BR (1) | BRPI0514829A (pt) |
CA (1) | CA2578014A1 (pt) |
CY (1) | CY1113554T1 (pt) |
DK (1) | DK1784419T3 (pt) |
ES (1) | ES2396422T3 (pt) |
GB (1) | GB0419408D0 (pt) |
HR (1) | HRP20130036T1 (pt) |
MX (1) | MX2007002094A (pt) |
NZ (1) | NZ553229A (pt) |
PL (1) | PL1784419T3 (pt) |
PT (1) | PT1784419E (pt) |
RS (1) | RS52634B (pt) |
RU (1) | RU2375374C2 (pt) |
SI (1) | SI1784419T1 (pt) |
WO (1) | WO2006024954A2 (pt) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2261339B1 (en) | 1998-05-01 | 2017-03-22 | GlaxoSmithKline Biologicals SA | Neisseria meningitidis antigens and compositions |
US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
WO2001031019A2 (en) | 1999-10-29 | 2001-05-03 | Chiron Spa | Neisserial antigenic peptides |
NZ545647A (en) * | 1999-05-19 | 2008-02-29 | Chiron Srl | Combination neisserial compositions |
PT1248647E (pt) * | 2000-01-17 | 2010-11-18 | Novartis Vaccines & Diagnostics Srl | Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b |
JP4846160B2 (ja) | 2000-02-28 | 2011-12-28 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ナイセリア属のタンパク質のハイブリッド発現 |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
DK1549338T3 (da) * | 2002-10-11 | 2011-03-28 | Novartis Vaccines & Diagnostic | Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier |
GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
GB0408977D0 (en) * | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
AU2013201318B2 (en) * | 2005-11-25 | 2015-11-19 | Glaxosmithkline Biologicals Sa | Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870 |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
CN102356089B (zh) | 2008-02-21 | 2014-02-19 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽 |
US9511131B2 (en) | 2008-03-10 | 2016-12-06 | Children's Hospital & Research Center Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
CA2726512A1 (en) * | 2008-06-09 | 2009-12-17 | Novartis Ag | Antibodies against neisserial factor h binding protein |
SI2411048T1 (sl) | 2009-03-24 | 2020-08-31 | Glaxosmithkline Biologicals Sa | Meningokokni faktor H vezavni protein uporabljen kot adjuvans |
JP5668049B2 (ja) * | 2009-03-24 | 2015-02-12 | ノバルティス アーゲー | 髄膜炎菌h因子結合タンパク質および肺炎球菌糖結合体の組み合わせ |
CN102711814A (zh) * | 2009-04-30 | 2012-10-03 | 奥克兰儿童医院及研究中心 | 一种嵌合h因子结合蛋白(fhbp)及其使用方法 |
US8858958B2 (en) | 2009-08-27 | 2014-10-14 | Novartis Ag | Adjuvant comprising aluminum, oligonucleotide and polycation |
EP2470204B1 (en) | 2009-08-27 | 2015-12-16 | GlaxoSmithKline Biologicals SA | Hybrid polypeptides including meningococcal fhbp sequences |
EP2483390A2 (en) | 2009-09-30 | 2012-08-08 | Novartis AG | Expression of meningococcal fhbp polypeptides |
AU2010310985B2 (en) | 2009-10-27 | 2014-11-06 | Glaxosmithkline Biologicals S.A. | Modified meningococcal fHBP polypeptides |
TR201802933T4 (tr) * | 2010-03-30 | 2018-03-21 | Childrens Hospital & Res Center At Oakland | Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi. |
EP2585106A1 (en) | 2010-06-25 | 2013-05-01 | Novartis AG | Combinations of meningococcal factor h binding proteins |
ES2850973T3 (es) | 2010-08-23 | 2021-09-01 | Wyeth Llc | Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis |
ES2728282T3 (es) | 2010-09-10 | 2019-10-23 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
WO2013098589A1 (en) | 2011-12-29 | 2013-07-04 | Novartis Ag | Adjuvanted combinations of meningococcal factor h binding proteins |
JP2015517089A (ja) * | 2012-03-08 | 2015-06-18 | ノバルティス アーゲー | タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
JP5925342B2 (ja) | 2012-03-09 | 2016-05-25 | ファイザー・インク | 髄膜炎菌(Neisseriameningitidis)組成物およびその方法 |
EP2861247B1 (en) | 2012-06-14 | 2020-12-09 | GlaxoSmithKline Biologicals SA | Vaccines for serogroup x meningococcus |
JP2015524418A (ja) | 2012-07-27 | 2015-08-24 | アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 血管内皮細胞への髄膜炎菌の線毛媒介接着の受容体としてのcd147 |
US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
JP2016527278A (ja) | 2013-08-02 | 2016-09-08 | チルドレンズ ホスピタル アンド リサーチ センター オークランド | 天然に生じないh因子結合タンパク質(fhbp)及びその使用の方法 |
BR112016004463A2 (pt) | 2013-09-08 | 2017-10-17 | Pfizer | composições de neisseria meningitidis e métodos das mesmas |
BR112016019735A2 (pt) | 2014-02-28 | 2017-10-17 | Glaxosmithkline Biologicals Sa | fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica |
CA2954729C (en) * | 2014-07-17 | 2023-08-22 | Glaxosmithkline Biologicals S.A. | Meningococcus vaccines |
JP2017522320A (ja) | 2014-07-17 | 2017-08-10 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 修飾された髄膜炎菌fhbpポリペプチド |
RU2714248C2 (ru) | 2014-07-23 | 2020-02-13 | Чилдрен'З Хоспитал Энд Рисёрч Сентер Эт Окленд | Варианты фактор н-связывающего белка и способы их применения |
US10888611B2 (en) | 2015-02-19 | 2021-01-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
US11066453B2 (en) | 2015-05-18 | 2021-07-20 | Biomvis Srl | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
GB201614687D0 (en) * | 2016-08-31 | 2016-10-12 | Univ Oxford Innovation Ltd | fHbp scaffold |
IL303108B1 (en) | 2017-01-31 | 2024-03-01 | Pfizer | NEISSERIA MENINGITIDIS preparations and methods therefor |
EP3536706A1 (en) | 2018-03-09 | 2019-09-11 | BiOMVis Srl | Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof |
EP3725371A1 (en) | 2019-04-18 | 2020-10-21 | BiOMVis Srl | Method for the production of outer membrane vesicles and immunogenic compositions thereof |
US20240016916A1 (en) | 2020-05-15 | 2024-01-18 | Biomvis S.R.L. | Bacterial outer membrane vesicles carrying coronavirus polypeptides, method of preparation, compositions and use thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
EP2261339B1 (en) | 1998-05-01 | 2017-03-22 | GlaxoSmithKline Biologicals SA | Neisseria meningitidis antigens and compositions |
NZ545647A (en) * | 1999-05-19 | 2008-02-29 | Chiron Srl | Combination neisserial compositions |
PT1248647E (pt) * | 2000-01-17 | 2010-11-18 | Novartis Vaccines & Diagnostics Srl | Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b |
JP4846160B2 (ja) * | 2000-02-28 | 2011-12-28 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ナイセリア属のタンパク質のハイブリッド発現 |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
MX339524B (es) * | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
US20060240045A1 (en) * | 2002-08-02 | 2006-10-26 | Francois-Xavier Berthet | Neisserial vaccine compositions comprising a combination of antigens |
US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
DK1549338T3 (da) * | 2002-10-11 | 2011-03-28 | Novartis Vaccines & Diagnostic | Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier |
GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
EP2289546A3 (en) * | 2003-01-30 | 2011-03-30 | Novartis Vaccines and Diagnostics S.r.l. | Injectable vaccines against multiple meningococcal serogroups |
EP1961426B1 (en) * | 2003-10-02 | 2011-04-27 | Novartis Vaccines and Diagnostics S.r.l. | Combined meningitis vaccines |
GB0524066D0 (en) * | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
SI2411048T1 (sl) * | 2009-03-24 | 2020-08-31 | Glaxosmithkline Biologicals Sa | Meningokokni faktor H vezavni protein uporabljen kot adjuvans |
-
2004
- 2004-09-01 GB GB0419408A patent/GB0419408D0/en not_active Ceased
-
2005
- 2005-09-01 SI SI200531651T patent/SI1784419T1/sl unknown
- 2005-09-01 US US11/661,665 patent/US20090285845A1/en not_active Abandoned
- 2005-09-01 RS RS20130004A patent/RS52634B/en unknown
- 2005-09-01 AU AU2005278904A patent/AU2005278904B2/en not_active Ceased
- 2005-09-01 CN CN2005800293251A patent/CN101031584B/zh not_active Expired - Fee Related
- 2005-09-01 PT PT05786178T patent/PT1784419E/pt unknown
- 2005-09-01 NZ NZ553229A patent/NZ553229A/en not_active IP Right Cessation
- 2005-09-01 WO PCT/IB2005/002968 patent/WO2006024954A2/en active Application Filing
- 2005-09-01 EP EP20050786178 patent/EP1784419B1/en active Active
- 2005-09-01 DK DK05786178T patent/DK1784419T3/da active
- 2005-09-01 BR BRPI0514829-4A patent/BRPI0514829A/pt not_active IP Right Cessation
- 2005-09-01 JP JP2007529041A patent/JP4827196B2/ja not_active Expired - Fee Related
- 2005-09-01 MX MX2007002094A patent/MX2007002094A/es active IP Right Grant
- 2005-09-01 PL PL05786178T patent/PL1784419T3/pl unknown
- 2005-09-01 RU RU2007111700A patent/RU2375374C2/ru not_active IP Right Cessation
- 2005-09-01 CA CA 2578014 patent/CA2578014A1/en not_active Abandoned
- 2005-09-01 ES ES05786178T patent/ES2396422T3/es active Active
-
2011
- 2011-05-19 JP JP2011112884A patent/JP2011168611A/ja not_active Withdrawn
-
2013
- 2013-01-17 HR HRP20130036TT patent/HRP20130036T1/hr unknown
- 2013-01-23 CY CY20131100064T patent/CY1113554T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
RU2007111700A (ru) | 2008-10-10 |
SI1784419T1 (sl) | 2013-02-28 |
WO2006024954A3 (en) | 2006-08-24 |
RS52634B (en) | 2013-06-28 |
WO2006024954A2 (en) | 2006-03-09 |
ES2396422T3 (es) | 2013-02-21 |
EP1784419A2 (en) | 2007-05-16 |
CN101031584B (zh) | 2012-09-05 |
CA2578014A1 (en) | 2006-03-09 |
MX2007002094A (es) | 2007-04-24 |
US20090285845A1 (en) | 2009-11-19 |
PT1784419E (pt) | 2013-01-15 |
EP1784419B1 (en) | 2012-10-24 |
CN101031584A (zh) | 2007-09-05 |
GB0419408D0 (en) | 2004-10-06 |
DK1784419T3 (da) | 2013-02-04 |
JP2011168611A (ja) | 2011-09-01 |
JP4827196B2 (ja) | 2011-11-30 |
WO2006024954A9 (en) | 2012-03-15 |
JP2008511306A (ja) | 2008-04-17 |
HRP20130036T1 (hr) | 2013-02-28 |
PL1784419T3 (pl) | 2013-03-29 |
AU2005278904B2 (en) | 2012-02-09 |
CY1113554T1 (el) | 2016-06-22 |
RU2375374C2 (ru) | 2009-12-10 |
NZ553229A (en) | 2010-07-30 |
AU2005278904A1 (en) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0514829A (pt) | domìnios e epitopos da proteìna meningocócica nmb1870 | |
BRPI0512569A (pt) | métodos para reduzir a formação de n-retinilideno-n-retiniletanolamina no olho de um mamìfero, para reduzir a formação de lipofuscina no olho de um mamìfero, para tratar degeneração macular relacionada com a idade na forma seca no olho de um mamìfero e para reduzir atrofia geográfica no olho de um humano | |
Pangburn | Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement | |
Borza et al. | The Goodpasture autoantigen: Identification of multiple cryptic epitopes on the NC1 domain of the α3 (IV) collagen chain | |
Sa E Cunha et al. | Neisseria meningitidis Opc invasin binds to the sulphated tyrosines of activated vitronectin to attach to and invade human brain endothelial cells | |
BRPI0210010B8 (pt) | imunógeno peptídico, bem como composição e aplicação compreendendo os mesmos | |
BRPI0507370A (pt) | derivados de indazol como inibidores da lipase sensìvel ao hormÈnio | |
BR0212999A (pt) | novas composições imunogênicas para a prevenção e tratamento de doença meningocócica | |
BRPI0310144A8 (pt) | vitreólise farmacológica | |
Miller et al. | Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited | |
BRPI0418766B8 (pt) | anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico | |
BR0308141A (pt) | composições e processo para o tratamento de problemas de peso corporal com minerais do leite e frações de caseìna | |
BRPI0513603A (pt) | uso de hidroxicarbonato de lantánio e composição farmacêutica | |
CN106282136A (zh) | 黄嘌呤氧化酶b细胞表位及包含此表位的抗原肽及其用途 | |
Plummer et al. | Relationship between the ability of oral streptococci to interact with platelet glycoprotein Ibα and with the salivary low-molecular-weight mucin, MG2 | |
BR122018077204B8 (pt) | peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica | |
Huang et al. | Self-oligomerization is essential for enhanced immunological activities of soluble recombinant calreticulin | |
BR0115045A (pt) | Compostos, processo para sua preparação, composição farmacêutica que compreende os mesmos, sua utilização, processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
BRPI0511624A (pt) | anticorpos e moléculas relacionadas que se ligam à proteìnas psca | |
Stoyanova et al. | New insight into the autoimmunogenicity of the complement protein C1q | |
Patrizi et al. | Keratosis lichenoides chronica: a pediatric case | |
UA107177C2 (uk) | Імуногенна композиція цвс2 та спосіб приготування такої композиції | |
Stabl et al. | A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression | |
BR0312461A (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e métodos para tratamento e profilaxia | |
Kuo et al. | Application of the C3-binding motif of streptococcal pyrogenic exotoxin B to protect mice from invasive group a streptococcal infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |